Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Ref Type||Journal Article|
|Authors||Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, Michielin O, Muehlethaler K, Speiser D, Beckmann JS, Xenarios I, Halazonetis TD, Jongeneel CV, Stevenson BJ, Antonarakis SE|
|Title||Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.|
|Abstract Text||We performed exome sequencing to detect somatic mutations in protein-coding regions in seven melanoma cell lines and donor-matched germline cells. All melanoma samples had high numbers of somatic mutations, which showed the hallmark of UV-induced DNA repair. Such a hallmark was absent in tumor sample-specific mutations in two metastases derived from the same individual. Two melanomas with non-canonical BRAF mutations harbored gain-of-function MAP2K1 and MAP2K2 (MEK1 and MEK2, respectively) mutations, resulting in constitutive ERK phosphorylation and higher resistance to MEK inhibitors. Screening a larger cohort of individuals with melanoma revealed the presence of recurring somatic MAP2K1 and MAP2K2 mutations, which occurred at an overall frequency of 8%. Furthermore, missense and nonsense somatic mutations were frequently found in three candidate melanoma genes, FAT4, LRP1B and DSC1.|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|FGFR2||R330W||missense||unknown||FGFR2 R330W lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). R330W has been identified in sequencing studies (PMID: 22197931), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2020).|
|MAP2K1||E203K||missense||gain of function||MAP2K1 E203K lies within the protein kinase domain of the Map2k1 protein (UniProt.org). E203K results in constitutive phosphorylation of Erk, is transforming in cell culture (PMID: 22197931, PMID: 29483135), and increases autophosphorylation of Map2k1 (PMID: 29753091).||Y|
|MAP2K1||N382H||missense||unknown||MAP2K1 N382H does not lie within any known functional domains of the Map2k1 protein (UniProt.org). N382H does not lead to Erk phosphorylation in culture (PMID: 22197931), however, has not been fully biochemically characterized and therefore, its effect on Map2k1 protein function is unknown.|
|MAP2K1||P124S||missense||unknown||MAP2K1 P124S lies within the protein kinase domain of the Map2k1 protein (UniProt.org). The functional effect of P124S is conflicting, as it has been reported to confer a gain of function on the Map2k1 protein as demonstrated by increased ERK1/2 phosphorylation, but has similar induction of cell proliferation and viability levels as wild-type Map2k1 (PMID: 29533785), and confers resistance to Mek and Braf inhibitors in melanoma cells (PMID: 19915144, PMID: 22197931).||Y|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E MAP2K1 P124S||melanoma||decreased response||Selumetinib||Preclinical||Actionable||In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).||22197931|